¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѴٹ߼º°æÈ­ÁõÇÐȸ 2018³â ¿¬·ÊÇмú´ëȸ : 2018-08-18

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇѴٹ߼º°æÈ­ÁõÇÐȸ 2018³â ¿¬·ÊÇмú´ëȸ : 2018-08-18
±³À°ÀÏÀÚ : 2018-08-18
±³À°Àå¼Ò : The K Hotel º°°ü 2Ãþ ±Ý°­È¦  
±³À°ÁÖÁ¦ : ´ëÇѴٹ߼º°æÈ­ÁõÇÐȸ 2018³â ¿¬·ÊÇмú´ëȸ      
ÁÖÃÖ±â°ü : ´ëÇѽŰæ°úÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѴٹ߼º°æÈ­ÁõÇÐȸ  
´ã´çÀÚ : ÇѴٹ߼º°æÈ­ÁõÇÐȸ
¿¬¶ôó : 02-720-1594  
À̸ÞÀÏ : ksms1594@hanmail.net      
±³À°Á¾·ù : ½Å°æ°ú      
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 30ºÐ  
¼¼ºÎ¼ö°­·á : 50,000¿ø      
ºñ°í »çÀüµî·Ï: Àü°øÀÇ 1¸¸¿ø, Àü¹®ÀÇ 3¸¸¿ø, ±âŸ:4¸¸¿ø / ´çÀϵî·Ï: Àü°øÀÇ 2¸¸¿ø, Àü¹®ÀÇ 4¸¸¿ø, ±âŸ: 5¸¸¿ø      
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 09:10~09:35 Multiple sclerosis (MS)  º¯¼Ò¿µ(±¹¸³°æÂûº´¿ø) 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 09:35~10:10 Neuromyelitis optica (NMO)  ¼®Èï¿­(°è¸íÀÇ´ë) 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 10:20~11:00 Human lymphocyte repertories analysis with next generation sequencing technology  Á¤ÁØÈ£(¼­¿ïÀÇ´ë, Ç×ü°øÇаú) 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 11:00~11:20 Overview  ±è¿ìÁØ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 11:20~11:40 Case-based learning I:Anti-MOG disease  ±è¼º¹Î(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 11:40~12:00 Case-based learning II:Systemic autoimmune disease  ±è¼±¿µ(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 12:00~12:20 Case-based learning III:Neoplastic and lymphoproliferative diseases  ÀÌÇý¸²(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 13:20~14:00 Poster Presentations  ÇмúÀ§¿øȸ Àüü() 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 14:00~14:50 Platform Presentations  ÀÌ»ó¼ö, ±èÈ£Áø(ÁÂÀå)(ÃæºÏÀÇ´ë, ±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 14:50~15:30 European and American new guidelines for MS treatment: how can the guidelines be adapted to clinical practice in Korea?  ±è¼öÇö(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 15:50~16:10 Kim MJ, Jeun SS, et al.(2017). ¡°Effective combination of methylprednisolone and interferon ¥â-secreting mesenchymal stem cells in a model of multiple sclerosis.¡±. J Neuroimmunol. 2018 Jan 15;314:81-88.  Àü½Å¼ö(°¡Å縯ÀÇ´ë, ½Å°æ¿Ü°ú) 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 16:10~16:30 Baek SH, Kim JS, et al.(2018). ¡°Low body mass index can be associated with the risk and poor outcomes of neuromyelitis optica with aquaporin-4 immunoglobulin G in women.¡± J Neurol Neurosurg Psychiatry. 2018 Jan 25.  ¹é¼³Èñ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 16:30~16:50 Hyun JW, Huh SY, et al.(2018). ¡°Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis.¡±. Mult Scler. 2018 Mar 7.  ÇöÀç¿ø(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 08¿ù 18ÀÏ 2Ãþ ±Ý°­È¦ 16:50~17:10 Seok JM, Choi MS , et al.(2017) ¡°Fatigue in patients with neuromyelitis optica spectrum disorder and its impact on quality of life.¡± PLoS One. 2017 May 23;12(5).  ¼®Áø¸í(¼º±Õ°üÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѴٹ߼º°æÈ­ÁõÇÐȸ 2018³â ¿¬·ÊÇмú´ëȸ : 2018-08-18""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѺ´¸®ÇÐȸ 8th Ç÷¾×º´¸® ¿¬¼ö±³À° : 2018-08-18
´ÙÀ½±Û ´ëÇÑÀ̺ñÀÎÈÄ°úÇÐȸ 2018³âµµ Á¦2Â÷ ÁöµµÀü¹®ÀÇ ±³À° : 2018-08-17
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21017 ´ë±¸ 2024 ´ëÇÑÀÀ±ÞÀÇÇÐȸ Ãá°èÇмú´ëȸ (1ÀÏÂ÷) : 2024-06-27 0 68 2024-06-18
21016 ºÎ»ê 2024 ±ÝÁ¤±¸ÀÇ»çȸ Çмú´ëȸ(¿¹¹æÁ¢Á¾, ÇʼöÀÇ·áÆÐÅ°Áö) : 2024-06-27 0 70 2024-06-18
21015 ¼­¿ï (¿Â¶óÀÎ) 2024³â Á¦1Â÷ ÇÑÀϺ´¿ø °³¿øÀÇ ¿¬¼ö°­Á : 2024-06-27 0 102 2024-06-18
21014 °æ³² Çѱ¹¿©ÀÚÀÇ»çȸ °æ³²Áöȸ 6¿ù Çмú½ÉÆ÷Áö¾ö : 2024-06-27 0 75 2024-06-18
21013 ¿ï»ê Á¦50ȸ ´ëÇÑ¿Ü°úÇÐȸ ¿ï»êÁöȸ : 2024-06-26 0 112 2024-06-18
21012 °æ±â ÀÌõ½ÃÀÇ»çȸ ¿¬¼ö°­ÁÂ(Æó±â´É°Ë»çÀÇ Çؼ®, õ½ÄÀÇ Áø´Ü°ú Ä¡·á) : 2024-06-26 0 93 2024-06-18
21011 ºÎ»ê 2024 »ç»ó±¸ÀÇ»çȸ Àü¹Ý±â Çмú´ëȸ(¸¸¼º±âħ, ÀÇ·á±â°ü Àλç³ë¹«) : 2024-06-26 0 83 2024-06-18
21010 ¼­¿ï (¿Â¶óÀÎ) ¼Ò¾Æû¼Ò³â°ú Çù·ÂÀÇ»ç Áý´ãȸ(Àú½ÅÀå°ú ¼ºÀåÈ£¸£¸ó Ä¡·á, ½Å»ý¾ÆÁúȯ) : 2024-06-25 0 92 2024-06-18
21009 ¼­¿ï (¿Â¶óÀÎ) ´ëÇѼҾư¨¿°ÇÐȸ Á¦192Â÷ ¿ù·Ê¿¬¼ö°­Á : 2024-06-25 0 102 2024-06-18
21008 ºÎ»ê ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ ºÎ»ê°æ³²Áöȸ Çмúȸ : 2024-06-25 0 97 2024-06-17
21007 °æ³² â¿ø½Ã ¼Ò¾Æû¼Ò³â°úÁöȸ ¿¬¼ö°­ÁÂ(¼Ò¾Æ ¼ÒÈ­±â Áúȯ) : 2024-06-25 0 125 2024-06-17
21006 Ãæ³² ´Ü±¹´ëÇб³º´¿ø À̺ñÀÎÈÄ°ú °³¿øÀÇ Çмúȸ(±¸°­°ÇÁ¶Áõ) : 2024-06-25 0 74 2024-06-17
21005 ¼­¿ï (¿Â¶óÀÎ) 2024³â 6¿ù ¼Ò¾Æ½ÉÃÊÀ½ÆÄ Áý´ãȸ : 2024-06-24 0 68 2024-06-17
21004 °æ±â 2024³â ¼Ò¾Æ¼ö¸é¿¬±¸È¸ Á¦2Â÷ Áý´ãȸ(¿Â¶óÀÎ) : 2024-06-24 0 76 2024-06-17
21003 Ãæ³² ´Ü±¹´ëÇб³º´¿ø À̺ñÀÎÈÄ°ú (¿Â¶óÀÎ) 29th Vestibular Function Test Workshop : 2024-06-23 0 22 2024-06-17
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷